胱天蛋白酶9

胱天蛋白酶9
已知的結構
PDB直系同源搜索: PDBe RCSB
識別號
别名CASP9;, APAF-3, APAF3, ICE-LAP6, MCH6, PPP1R56, caspase 9
外部IDOMIM602234 MGI1277950 HomoloGene31024 GeneCardsCASP9
為以下藥物的標靶
emricasan[1]
基因位置(人类
1號染色體
染色体1號染色體[2]
1號染色體
胱天蛋白酶9的基因位置
胱天蛋白酶9的基因位置
基因座1p36.21起始15,490,832 bp[2]
终止15,526,534 bp[2]
RNA表达模式


查阅更多表达数据
直系同源
物種人類小鼠
Entrez
Ensembl
UniProt
mRNA​序列

NM_001229
​NM_001278054
​NM_032996

NM_001277932
​NM_015733
​NM_001355176

蛋白序列

NP_001220
​NP_001264983
​NP_127463

NP_001264861
​NP_056548
​NP_001342105

基因位置​(UCSC)Chr 1: 15.49 – 15.53 MbChr 4: 141.52 – 141.54 Mb
PubMed​查找[4][5]
維基數據
檢視/編輯人類檢視/編輯小鼠

胱天蛋白酶9英语:Caspase 9)是人类中由CASP9基因编码的一种。它是一种启动型胱天蛋白酶[6]对于许多组织中发现的细胞凋亡途径至关重要。[7]已经在已知存在的所有哺乳动物中发现了胱天蛋白酶9同源物,如小鼠Mus musculus)和黑猩猩Pan troglodytes)。[8]

胱天蛋白酶9属于胱天蛋白酶家族,主要参与细胞凋亡细胞因子信号转导。[9]凋亡信号导致线粒体释放细胞色素c并激活apaf-1凋亡复合体),然后将胱天蛋白酶9的酶原裂解为活性二聚体形式。[7]这种酶的调节是通过异构抑制剂磷酸化来实现的,抑制二聚化并诱导构象变化[9]

正确的胱天蛋白酶9功能对于细胞凋亡至关重要,有助于中枢神经系统的正常发育。[9]胱天蛋白酶9还具有多种与其在细胞凋亡中的作用无关的附加细胞功能。胱天蛋白酶9的非凋亡作用包括调节程序性坏死细胞分化先天免疫反应感觉神经元成熟、线粒体稳态、皮质脊髓路径组织和缺血性血管损伤。[10]如果没有正确的功能,可能导致异常的组织发育,引发功能异常、疾病和过早死亡。[9]胱天蛋白酶9缺失功能突变与免疫缺陷/淋巴增生性障碍神经管缺陷以及类李-佛美尼症候群有关。胱天蛋白酶9活性增加与肌萎缩性脊髓侧索硬化症视网膜脱离和慢通道综合症,以及各种神经自身免疫心血管疾病的发展有关。[10]

由于选择性剪接,产生了不同的胱天蛋白酶9蛋白质亚型。[11]

结构

与其他胱天蛋白酶类似,胱天蛋白酶9具有三个结构域:N端前结构域、大亚基和小亚基。[9]端前结构域也称为长前结构域,其中包含胱天蛋白酶激活结构域(CARD基序[12]前结构域通过连接环与催化结构域连接。[13]

胱天蛋白酶9单体由一大一小亚基组成,均包含催化结构域[14]与其他胱天蛋白酶中通常保守的活性位点基序QACRG不同,胱天蛋白酶9具有基序QACGG。[15][13]

当二聚化时,胱天蛋白酶9在每个二聚体中具有两种不同的活性位点构象。[14]其中一个位点与其他胱天蛋白酶的催化位点非常相似;而第二个位点没有“激活环”,会破坏该特定活性位点的催化机制。[14]活性位点周围的表面环很短,底物结合裂缝更开放,因此产生了广泛的底物特异性。[16]在胱天蛋白酶9的活性位点内,必须有特定的氨基酸位于正确的位置,才能产生催化活性。位于P1位的氨基酸Asp是必需的,而位于P2位的氨基酸His更受青睐。[17]

定位

人类的胱天蛋白酶9存在于线粒体细胞质细胞核中。[18]

蛋白质表达

人类的胱天蛋白酶9在胎儿和成人组织中表达。[15][13]该酶的组织表达无处不在,在大脑心脏中表达最高,特别是在成人发育阶段的心脏肌肉细胞中。[19]肝脏胰腺骨骼肌以中等水平表达该酶,而所有其他组织以低水平表达该酶。[19]

机制

激活的胱天蛋白酶9充当启动型胱天蛋白酶,通过裂解从而激活下游执行型胱天蛋白酶,从而引发细胞凋亡。[20]一旦激活,胱天蛋白酶9就会继续裂解胱天蛋白酶3、6和7,这些酶会裂解其他细胞靶点而启动胱天蛋白酶级联反应[9]

当胱天蛋白酶9失活时,它以单体形式作为酶原存在于细胞质中。[14][21]然后被apaf-1中的CARD通过识别胱天蛋白酶9中的CARD招募并激活。[22]

加工

在激活之前,胱天蛋白酶9必须经过加工处理。[23]最初,胱天蛋白酶9被制成无活性的单链酶原。[23]当凋亡复合体与胱天蛋白酶9前体结合时,加工就会发生,因为apaf-1有助于酶原的自蛋白水解加工。[23]加工后的胱天蛋白酶9与凋亡体复合物结合,形成全酶。[24]

激活

胱天蛋白酶9二聚化时会发生激活,有两种不同的方式可以实现:

  1. 胱天蛋白酶9在与apaf-1(凋亡复合体)结合时会自动激活,因为apaf-1会寡聚胱天蛋白酶9前体分子。[18]
  2. 先前激活的胱天蛋白酶可以裂解胱天蛋白酶9,导致其二聚化。[25]

催化活性

胱天蛋白酶9的优选切割序列为Leu-Gly-His-Asp-(cut)-X。[17]

调节

胱天蛋白酶9的负调节通过磷酸化发生。[9]这是通过丝氨酸-196上的丝氨酸-苏氨酸激酶Akt来完成的,它抑制胱天蛋白酶9的激活和蛋白酶活性,从而抑制胱天蛋白酶9及细胞凋亡的进一步激活。[26]Akt充当胱天蛋白酶9的变构抑制剂,因为丝氨酸-196的磷酸化位点离催化位点很远。[26]该抑制剂影响胱天蛋白酶9的二聚化并引起构象变化,从而影响胱天蛋白酶9的底物结合裂口。[26]

Akt可以在体外作用于加工过的和未加工过的胱天蛋白酶9,其中加工过的胱天蛋白酶9的磷酸化发生在大亚基上。[27]

缺陷和突变

缺乏胱天蛋白酶9很大程度上会影响大脑及其发育。[28]与其他胱天蛋白酶相比,这种胱天蛋白酶的突变或缺陷的影响是有害的。[28]在细胞凋亡中,胱天蛋白酶9发挥的起始作用是导致那些患有非典型胱天蛋白酶9的人出现严重影响的原因。

胱天蛋白酶9不足的小鼠具有受影响或异常大脑的主要表型[9]由于细胞凋亡减少而导致大脑变大,从而导致额外神经元的增加,这是在胱天蛋白酶9缺陷小鼠中观察到的表型的一个例子。[29]那些没有胱天蛋白酶9的纯合子会因大脑发育异常而在围产期死亡[9]

在人类中,胱天蛋白酶9的表达因组织而异,并且不同水平具有生理作用。[29]低含量的胱天蛋白酶9会导致癌症神经退行性疾病阿尔茨海默病等。[29]胱天蛋白酶9单核苷酸多态性(SNP)水平和全基因水平的进一步改变可能导致与非霍奇金淋巴瘤相关的生殖系突变[30]胱天蛋白酶9启动子中的某些多态性会提高胱天蛋白酶9的表达率,这会增加人患肺癌的风险。[31]

临床意义

胱天蛋白酶9水平或功能异常会影响临床界。胱天蛋白酶9对大脑的影响可能会引领未来通过靶向治疗进行抑制研究,特别是与大脑相关的疾病,因为这种酶可能参与神经元疾病的发展途径。[9]

胱天蛋白酶的引入也可能具有医疗益处。[20]移植物对抗宿主疾病的背景下,可以引入胱天蛋白酶9作为诱导开关。[32]当小分子存在时,它会二聚化并引发细胞凋亡,消除淋巴细胞[32]

iCasp9

iCasp9(诱导型胱天蛋白酶9)是一种嵌合抗原受体T细胞(CAR T细胞)的控制系统。CAR T细胞是经过基因改造的T细胞,对肿瘤细胞具有细胞毒性。有证据表明CAR T细胞可有效治疗B细胞恶性肿瘤。然而,由于CAR T细胞会产生毒性,因此对细胞及其靶点的用户控制至关重要。[33]对CAR T细胞进行控制的多种方法之一是通过药物控制的合成系统。iCasp9是通过修饰胱天蛋白酶9并将其与FK506结合蛋白融合而创建的。[33]iCasp9可以作为诱导性自杀基因添加到CAR T细胞中。[34]

如果CAR T细胞治疗导致严重副作用,iCasp9可用于停止治疗。给予雷帕霉素等小分子药物会导致药物与FK506结构域结合。[34]这反过来会诱导胱天蛋白酶9的表达,从而触发CAR T细胞的细胞死亡。[34]

替代转录

通过选择性剪接可产生了四种不同的胱天蛋白酶9变体。

胱天蛋白酶9α(9L)

该变体用作参考序列,它具有完整的半胱氨酸蛋白酶活性。[12][35]

胱天蛋白酶9β(9S)

异构体2不包括外显子3、4、5和6,它缺少氨基酸140-289。[12][35]胱天蛋白酶9S没有中心催化结构域,因此它通过附着在凋亡体上作为胱天蛋白酶9α的抑制剂,抑制胱天蛋白酶级联和细胞凋亡。[12][36]胱天蛋白酶9β被称为内源性显性失活亚型。

胱天蛋白酶9γ

该变体缺少氨基酸155-416,并且对于氨基酸152-154,序列AYI更改为TVL。[35]

异构体4

与参考序列相比,它缺少氨基酸1-83。[35]

相互作用

胱天蛋白酶9已被证明可以与以下物质相互作用

细胞凋亡涉及的信号转导途径概述。

参见

参考文献

  1. ^ 對Caspase 9起作用的藥物;在維基數據上查看/編輯參考. 
  2. ^ 2.0 2.1 2.2 GRCh38: Ensembl release 89: ENSG00000132906 - Ensembl, May 2017
  3. ^ 3.0 3.1 3.2 GRCm38: Ensembl release 89: ENSMUSG00000028914 - Ensembl, May 2017
  4. ^ Human PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine. 
  5. ^ Mouse PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine. 
  6. ^ MeSH Browser. meshb.nlm.nih.gov. [2024-02-14]. (原始内容存档于2024-02-22). 
  7. ^ 7.0 7.1 7.2 Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. November 1997, 91 (4): 479–89. PMID 9390557. S2CID 14321446. doi:10.1016/s0092-8674(00)80434-1可免费查阅. 
  8. ^ HomoloGene - NCBI. www.ncbi.nlm.nih.gov. [2017-12-01]. (原始内容存档于2023-07-18). 
  9. ^ 9.00 9.01 9.02 9.03 9.04 9.05 9.06 9.07 9.08 9.09 Kuida K. Caspase-9. The International Journal of Biochemistry & Cell Biology. 2000, 32 (2): 121–4. PMID 10687948. doi:10.1016/s1357-2725(99)00024-2. 
  10. ^ 10.0 10.1 Avrutsky MI, Troy CM. Caspase-9: A Multimodal Therapeutic Target With Diverse Cellular Expression in Human Disease. Frontiers in Pharmacology. 2021, 12: 701301. PMC 8299054可免费查阅. PMID 34305609. doi:10.3389/fphar.2021.701301可免费查阅. 
  11. ^ CASP9 caspase 9 [Homo sapiens (human)] - Gene - NCBI. www.ncbi.nlm.nih.gov. [2017-11-30]. (原始内容存档于2024-02-17). 
  12. ^ 12.0 12.1 12.2 12.3 Li P, Zhou L, Zhao T, Liu X, Zhang P, Liu Y, Zheng X, Li Q. Caspase-9: structure, mechanisms and clinical application. Oncotarget. April 2017, 8 (14): 23996–24008. PMC 5410359可免费查阅. PMID 28177918. doi:10.18632/oncotarget.15098. 
  13. ^ 13.0 13.1 13.2 Srinivasula SM, Fernandes-Alnemri T, Zangrilli J, Robertson N, Armstrong RC, Wang L, Trapani JA, Tomaselli KJ, Litwack G, Alnemri ES. The Ced-3/interleukin 1beta converting enzyme-like homolog Mch6 and the lamin-cleaving enzyme Mch2alpha are substrates for the apoptotic mediator CPP32. The Journal of Biological Chemistry. October 1996, 271 (43): 27099–106. PMID 8900201. doi:10.1074/jbc.271.43.27099可免费查阅. 
  14. ^ 14.0 14.1 14.2 14.3 Renatus M, Stennicke HR, Scott FL, Liddington RC, Salvesen GS. Dimer formation drives the activation of the cell death protease caspase 9. Proceedings of the National Academy of Sciences of the United States of America. December 2001, 98 (25): 14250–5. Bibcode:2001PNAS...9814250R. PMC 64668可免费查阅. PMID 11734640. doi:10.1073/pnas.231465798可免费查阅. 
  15. ^ 15.0 15.1 Duan H, Orth K, Chinnaiyan AM, Poirier GG, Froelich CJ, He WW, Dixit VM. ICE-LAP6, a novel member of the ICE/Ced-3 gene family, is activated by the cytotoxic T cell protease granzyme B. The Journal of Biological Chemistry. July 1996, 271 (28): 16720–4. PMID 8663294. doi:10.1074/jbc.271.28.16720可免费查阅. 
  16. ^ Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Garcia-Calvo M, Houtzager VM, Nordstrom PA, Roy S, Vaillancourt JP, Chapman KT, Nicholson DW. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. The Journal of Biological Chemistry. July 1997, 272 (29): 17907–11. PMID 9218414. doi:10.1074/jbc.272.29.17907可免费查阅. 
  17. ^ 17.0 17.1 Blasche S, Mörtl M, Steuber H, Siszler G, Nisa S, Schwarz F, Lavrik I, Gronewold TM, Maskos K, Donnenberg MS, Ullmann D, Uetz P, Kögl M. The E. coli effector protein NleF is a caspase inhibitor. PLOS ONE. 2013-03-14, 8 (3): e58937. Bibcode:2013PLoSO...858937B. PMC 3597564可免费查阅. PMID 23516580. doi:10.1371/journal.pone.0058937可免费查阅. 
  18. ^ 18.0 18.1 Zhivotovsky B, Samali A, Gahm A, Orrenius S. Caspases: their intracellular localization and translocation during apoptosis. Cell Death and Differentiation. July 1999, 6 (7): 644–51. PMID 10453075. doi:10.1038/sj.cdd.4400536可免费查阅. 
  19. ^ 19.0 19.1 Han Y, Chen YS, Liu Z, Bodyak N, Rigor D, Bisping E, Pu WT, Kang PM. Overexpression of HAX-1 protects cardiac myocytes from apoptosis through caspase-9 inhibition. Circulation Research. August 2006, 99 (4): 415–23. PMID 16857965. doi:10.1161/01.RES.0000237387.05259.a5可免费查阅. 
  20. ^ 20.0 20.1 McIlwain DR, Berger T, Mak TW. Caspase functions in cell death and disease. Cold Spring Harbor Perspectives in Biology. April 2013, 5 (4): a008656. PMC 3683896可免费查阅. PMID 23545416. doi:10.1101/cshperspect.a008656. 
  21. ^ McIlwain DR, Berger T, Mak TW. Caspase functions in cell death and disease. Cold Spring Harbor Perspectives in Biology. April 2013, 5 (4): a008656. PMC 3683896可免费查阅. PMID 23545416. doi:10.1101/cshperspect.a008656. 
  22. ^ Acehan D, Jiang X, Morgan DG, Heuser JE, Wang X, Akey CW. Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Molecular Cell. 2002, 9 (2): 423–32. PMID 11864614. doi:10.1016/s1097-2765(02)00442-2可免费查阅. 
  23. ^ 23.0 23.1 23.2 Hu Q, Wu D, Chen W, Yan Z, Shi Y. Proteolytic processing of the caspase-9 zymogen is required for apoptosome-mediated activation of caspase-9. The Journal of Biological Chemistry. May 2013, 288 (21): 15142–7. PMC 3663534可免费查阅. PMID 23572523. doi:10.1074/jbc.M112.441568可免费查阅. 
  24. ^ Mace PD, Riedl SJ. Molecular cell death platforms and assemblies. Current Opinion in Cell Biology. December 2010, 22 (6): 828–36. PMC 2993832可免费查阅. PMID 20817427. doi:10.1016/j.ceb.2010.08.004. 
  25. ^ Druskovic M, Suput D, Milisav I. Overexpression of caspase-9 triggers its activation and apoptosis in vitro. Croatian Medical Journal. December 2006, 47 (6): 832–40. PMC 2080483可免费查阅. PMID 17167855. 
  26. ^ 26.0 26.1 26.2 Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC. Regulation of cell death protease caspase-9 by phosphorylation. Science. November 1998, 282 (5392): 1318–21. Bibcode:1998Sci...282.1318C. PMID 9812896. doi:10.1126/science.282.5392.1318. 
  27. ^ Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC. Regulation of cell death protease caspase-9 by phosphorylation. Science. November 1998, 282 (5392): 1318–21. Bibcode:1998Sci...282.1318C. PMID 9812896. doi:10.1126/science.282.5392.1318. 
  28. ^ 28.0 28.1 Madden SD, Cotter TG. Cell death in brain development and degeneration: control of caspase expression may be key!. Molecular Neurobiology. February 2008, 37 (1): 1–6. PMID 18449809. S2CID 12980212. doi:10.1007/s12035-008-8021-4. 
  29. ^ 29.0 29.1 29.2 Hakem R, Hakem A, Duncan GS, Henderson JT, Woo M, Soengas MS, Elia A, de la Pompa JL, Kagi D, Khoo W, Potter J, Yoshida R, Kaufman SA, Lowe SW, Penninger JM, Mak TW. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell. 1998, 94 (3): 339–52. PMID 9708736. S2CID 14390544. doi:10.1016/s0092-8674(00)81477-4可免费查阅. 
  30. ^ Kelly JL, Novak AJ, Fredericksen ZS, Liebow M, Ansell SM, Dogan A, Wang AH, Witzig TE, Call TG, Kay NE, Habermann TM, Slager SL, Cerhan JR. Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphoma. Cancer Epidemiology, Biomarkers & Prevention. November 2010, 19 (11): 2847–58. PMC 2976783可免费查阅. PMID 20855536. doi:10.1158/1055-9965.EPI-10-0581. 
  31. ^ Park JY, Park JM, Jang JS, Choi JE, Kim KM, Cha SI, Kim CH, Kang YM, Lee WK, Kam S, Park RW, Kim IS, Lee JT, Jung TH. Caspase 9 promoter polymorphisms and risk of primary lung cancer. Human Molecular Genetics. June 2006, 15 (12): 1963–71. PMID 16687442. doi:10.1093/hmg/ddl119可免费查阅. 
  32. ^ 32.0 32.1 Straathof KC, Pulè MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, Heslop HE, Spencer DM, Rooney CM. An inducible caspase 9 safety switch for T-cell therapy. Blood. June 2005, 105 (11): 4247–54. PMC 1895037可免费查阅. PMID 15728125. doi:10.1182/blood-2004-11-4564. 
  33. ^ 33.0 33.1 Choe JH, Williams JZ, Lim WA. Engineering T Cells to Treat Cancer: The Convergence of Immuno-Oncology and Synthetic Biology. Annual Review of Cancer Biology. 2020, 4: 121–139. doi:10.1146/annurev-cancerbio-030419-033657可免费查阅. 
  34. ^ 34.0 34.1 34.2 Definition of autologous iCASP9-CD19-expressing T lymphocytes. National Cancer Institute. [2020-07-02]. (原始内容存档于2023-09-24). 
  35. ^ 35.0 35.1 35.2 35.3 CASP9 - Caspase-9 precursor - Homo sapiens (Human) - CASP9 gene & protein. www.uniprot.org. [2017-12-01]. (原始内容存档于2024-02-17). 
  36. ^ Vu NT, Park MA, Shultz JC, Goehe RW, Hoeferlin LA, Shultz MD, Smith SA, Lynch KW, Chalfant CE. hnRNP U enhances caspase-9 splicing and is modulated by AKT-dependent phosphorylation of hnRNP L. The Journal of Biological Chemistry. March 2013, 288 (12): 8575–84. PMC 3605676可免费查阅. PMID 23396972. doi:10.1074/jbc.M112.443333可免费查阅. 
  37. ^ 37.0 37.1 Chu ZL, Pio F, Xie Z, Welsh K, Krajewska M, Krajewski S, Godzik A, Reed JC. A novel enhancer of the Apaf1 apoptosome involved in cytochrome c-dependent caspase activation and apoptosis. The Journal of Biological Chemistry. March 2001, 276 (12): 9239–45. PMID 11113115. doi:10.1074/jbc.M006309200可免费查阅. 
  38. ^ Cho DH, Hong YM, Lee HJ, Woo HN, Pyo JO, Mak TW, Jung YK. Induced inhibition of ischemic/hypoxic injury by APIP, a novel Apaf-1-interacting protein. The Journal of Biological Chemistry. September 2004, 279 (38): 39942–50. PMID 15262985. doi:10.1074/jbc.M405747200可免费查阅. 
  39. ^ Hu Y, Benedict MA, Wu D, Inohara N, Núñez G. Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proceedings of the National Academy of Sciences of the United States of America. April 1998, 95 (8): 4386–91. Bibcode:1998PNAS...95.4386H. PMC 22498可免费查阅. PMID 9539746. doi:10.1073/pnas.95.8.4386可免费查阅. 
  40. ^ Pan G, O'Rourke K, Dixit VM. Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex. The Journal of Biological Chemistry. March 1998, 273 (10): 5841–5. PMID 9488720. doi:10.1074/jbc.273.10.5841可免费查阅. 
  41. ^ 41.0 41.1 41.2 Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. The EMBO Journal. April 1998, 17 (8): 2215–23. PMC 1170566可免费查阅. PMID 9545235. doi:10.1093/emboj/17.8.2215. 
  42. ^ Guo Y, Srinivasula SM, Druilhe A, Fernandes-Alnemri T, Alnemri ES. Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. The Journal of Biological Chemistry. April 2002, 277 (16): 13430–7. PMID 11832478. doi:10.1074/jbc.M108029200可免费查阅. 
  43. ^ Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Litwack G, Alnemri ES. Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. Proceedings of the National Academy of Sciences of the United States of America. December 1996, 93 (25): 14486–91. Bibcode:1996PNAS...9314486S. PMC 26159可免费查阅. PMID 8962078. doi:10.1073/pnas.93.25.14486可免费查阅. 
  44. ^ Hlaing T, Guo RF, Dilley KA, Loussia JM, Morrish TA, Shi MM, Vincenz C, Ward PA. Molecular cloning and characterization of DEFCAP-L and -S, two isoforms of a novel member of the mammalian Ced-4 family of apoptosis proteins. The Journal of Biological Chemistry. March 2001, 276 (12): 9230–8. PMID 11076957. doi:10.1074/jbc.M009853200可免费查阅. 
  45. ^ Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, Li N, Berriz GF, Gibbons FD, Dreze M, Ayivi-Guedehoussou N, Klitgord N, Simon C, Boxem M, Milstein S, Rosenberg J, Goldberg DS, Zhang LV, Wong SL, Franklin G, Li S, Albala JS, Lim J, Fraughton C, Llamosas E, Cevik S, Bex C, Lamesch P, Sikorski RS, Vandenhaute J, Zoghbi HY, Smolyar A, Bosak S, Sequerra R, Doucette-Stamm L, Cusick ME, Hill DE, Roth FP, Vidal M. Towards a proteome-scale map of the human protein-protein interaction network. Nature. October 2005, 437 (7062): 1173–8. Bibcode:2005Natur.437.1173R. PMID 16189514. S2CID 4427026. doi:10.1038/nature04209. 
  46. ^ Davoodi J, Lin L, Kelly J, Liston P, MacKenzie AE. Neuronal apoptosis-inhibitory protein does not interact with Smac and requires ATP to bind caspase-9. The Journal of Biological Chemistry. September 2004, 279 (39): 40622–8. PMID 15280366. doi:10.1074/jbc.M405963200可免费查阅. 
  47. ^ Richter BW, Mir SS, Eiben LJ, Lewis J, Reffey SB, Frattini A, Tian L, Frank S, Youle RJ, Nelson DL, Notarangelo LD, Vezzoni P, Fearnhead HO, Duckett CS. Molecular cloning of ILP-2, a novel member of the inhibitor of apoptosis protein family. Molecular and Cellular Biology. July 2001, 21 (13): 4292–301. PMC 87089可免费查阅. PMID 11390657. doi:10.1128/MCB.21.13.4292-4301.2001. 

拓展阅读

外部链接